{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T22:20:07Z","timestamp":1775600407620,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","nmd-journal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.nmd.2024.05.003","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T02:04:27Z","timestamp":1715220267000},"page":"42-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Changes in abilities over the initial 12 months of nusinersen treatment for type II SMA"],"prefix":"10.1016","volume":"41","author":[{"given":"Giorgia","family":"Coratti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Civitello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemarie","family":"Rohwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Salmin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan M","family":"Glanzman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaqueline","family":"Montes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Pasternak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"De Sanctis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally Dunaway","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Duong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Mizzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelin","family":"Milev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Sframeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Morando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Albamonte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adele","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noemi","family":"Brolatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marika","family":"Pane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariacristina","family":"Scoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Messina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zarazuela","family":"Zolkipli-Cunningham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basil T","family":"Darras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Bertini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria A","family":"Sansone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Day","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Baranello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Carmela","family":"Pera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Finkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9851-5365","authenticated-orcid":false,"given":"Eugenio","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2024.05.003_bib0001","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","article-title":"Spinal muscular atrophy","volume":"33","author":"Kolb","year":"2015","journal-title":"Neurol Clin"},{"key":"10.1016\/j.nmd.2024.05.003_bib0002","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0960-8966(91)90051-S","article-title":"Chaos in classification of the spinal muscular atrophies of childhood","volume":"1","author":"Dubowitz","year":"1991","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2024.05.003_bib0003","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0960-8966(94)00075-K","article-title":"Chaos in the classification of SMA: a possible resolution","volume":"5","author":"Dubowitz","year":"1995","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2024.05.003_bib0004","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.nmd.2020.07.005","article-title":"Age and baseline values predict 12 and 24-month functional changes in type 2 SMA","volume":"30","author":"Coratti","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2024.05.003_bib0005","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000008166","article-title":"Long-term progression in type II spinal muscular atrophy: a retrospective observational study","volume":"93","author":"Mercuri","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2024.05.003_bib0006","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.nmd.2020.07.004","article-title":"Gain and loss of abilities in type II SMA: a 12-month natural history study","volume":"30","author":"Coratti","year":"2020","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2024.05.003_bib0007","article-title":"Spinal muscular atrophy: from approved therapies to future therapeutic targets for personalized medicine","volume":"2","author":"Chaytow","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.nmd.2024.05.003_bib0008","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9072222","article-title":"New treatments in spinal muscular atrophy: positive results and new challenges","volume":"9","author":"Messina","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.nmd.2024.05.003_bib0009","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","article-title":"Nusinersen: first global approval","volume":"77","author":"Hoy","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.nmd.2024.05.003_bib0010","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s13023-021-02065-z","article-title":"Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis","volume":"16","author":"Coratti","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2024.05.003_bib0011","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/brain\/awac252","article-title":"Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy","volume":"146","author":"Pechmann","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.nmd.2024.05.003_bib0012","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3233\/JND-221600","article-title":"Improvements in walking distance during nusinersen treatment - a prospective 3-year SMArtCARE registry study","volume":"10","author":"Pechmann","year":"2023","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2024.05.003_bib0013","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12154901","article-title":"Nusinersen treatment of children with later-onset spinal muscular atrophy and scoliosis is associated with improvements or stabilization of motor function","volume":"12","author":"Dunaway Young","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.nmd.2024.05.003_bib0014","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.nmd.2022.02.001","article-title":"Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland","volume":"32","author":"Tscherter","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2024.05.003_bib0015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study","volume":"19","author":"Hagenacker","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2024.05.003_bib0016","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","article-title":"Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study","volume":"29","author":"De Vivo","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2024.05.003_bib0017","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/acn3.51514","article-title":"Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy","volume":"9","author":"Pane","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.nmd.2024.05.003_bib0018","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13023-020-01414-8","article-title":"Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study","volume":"15","author":"Audic","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2024.05.003_bib0019","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.neurol.2021.10.010","article-title":"Nusinersen treatment in adults with severe spinal muscular atrophy: a real-life retrospective observational cohort study","volume":"178","author":"Lefeuvre","year":"2022","journal-title":"Rev Neurol"},{"key":"10.1016\/j.nmd.2024.05.003_bib0020","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","article-title":"An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients","volume":"17","author":"O'Hagen","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2024.05.003_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221097","article-title":"Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy","volume":"14","author":"Muntoni","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.nmd.2024.05.003_bib0022","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.nmd.2023.11.011","article-title":"Gain and loss of upper limb abilities in Duchenne muscular dystrophy patients: a 24-month study","volume":"34","author":"Coratti","year":"2023","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2024.05.003_bib0023","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.nmd.2019.08.014","article-title":"Development of an academic disease registry for spinal muscular atrophy","volume":"29","author":"Mercuri","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2024.05.003_bib0024","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1177\/0883073811420294","article-title":"Validation of the Expanded Hammersmith Functional Motor Scale in spinal muscular atrophy type II and III","volume":"26","author":"Glanzman","year":"2011","journal-title":"J Child Neurol"},{"key":"10.1016\/j.nmd.2024.05.003_bib0025","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3233\/JND-180301","article-title":"Evaluator training and reliability for SMA global nusinersen trials1","volume":"5","author":"Glanzman","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2024.05.003_bib0026","unstructured":"Dancey C., Reidy J., Statistics without maths for psychology. 2004."},{"key":"10.1016\/j.nmd.2024.05.003_bib0027","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/dmcn.12213","article-title":"Development of the performance of the upper limb module for duchenne muscular dystrophy","volume":"55","author":"Mayhew","year":"2013","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.nmd.2024.05.003_bib0028","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/pri.520","article-title":"Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy","volume":"17","author":"Scott","year":"2012","journal-title":"Physiother Res Int"},{"key":"10.1016\/j.nmd.2024.05.003_bib0029","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12883-017-0790-9","article-title":"Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy","volume":"17","author":"Pera","year":"2017","journal-title":"BMC Neurol"},{"key":"10.1016\/j.nmd.2024.05.003_bib0030","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12134183","article-title":"Caregivers' expectations on possible functional changes following disease-modifying treatment in type II and III spinal muscular atrophy: a comparative study","volume":"12","author":"Pera","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.nmd.2024.05.003_bib0031","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1111\/ene.15542","article-title":"Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy","volume":"29","author":"Vazquez-Costa","year":"2022","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nmd.2024.05.003_bib0032","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/PHM.0000000000001869","article-title":"Systematic review of motor function scales and patient-reported outcomes in spinal muscular atrophy","volume":"101","author":"Wu","year":"2022","journal-title":"Am J Phys Med Rehabil"},{"key":"10.1016\/j.nmd.2024.05.003_bib0033","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/mus.27384","article-title":"Different trajectories in upper limb and gross motor function in spinal muscular atrophy","volume":"64","author":"Coratti","year":"2021","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2024.05.003_bib0034","unstructured":"Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy TreatedWith Nusinersen or Risdiplam; 2021. p. NCT05156320."},{"key":"10.1016\/j.nmd.2024.05.003_bib0035","unstructured":"Long-term follow-up study for patients from AVXS-101-CL-101. 2019. NCT03421977"},{"key":"10.1016\/j.nmd.2024.05.003_bib0036","unstructured":"A Study of Nusinersen Among Participants With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec; 2020. p. NCT04488133."},{"key":"10.1016\/j.nmd.2024.05.003_bib0037","unstructured":"Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials; 2022. p. NCT05335876."},{"key":"10.1016\/j.nmd.2024.05.003_bib0038","unstructured":"Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam; 2022. p. NCT05386680."}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896624001007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896624001007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T03:15:46Z","timestamp":1722050146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896624001007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":38,"alternative-id":["S0960896624001007"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2024.05.003","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in abilities over the initial 12 months of nusinersen treatment for type II SMA","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2024.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}